Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.

Navas-Madroñal M, Valero-Mut A, Martínez-Zapata MJ, Simón-Talero MJ, Figueroa S, Vidal-Fernández N, López-Góngora M, Escartín A, Querol L.

PLoS One. 2017 Apr 17;12(4):e0175538. doi: 10.1371/journal.pone.0175538. eCollection 2017.

2.

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.

Nerrant E, Salsac C, Charif M, Ayrignac X, Carra-Dalliere C, Castelnovo G, Goulabchand R, Tisseyre J, Raoul C, Eliaou JF, Labauge P, Vincent T.

Mult Scler. 2014 Nov;20(13):1699-703. doi: 10.1177/1352458514531086. Epub 2014 Apr 22.

PMID:
24756568
3.

Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.

Marnetto F, Valentino P, Caldano M, Bertolotto A.

J Immunol Methods. 2017 Jun;445:53-58. doi: 10.1016/j.jim.2017.03.008. Epub 2017 Mar 12.

PMID:
28300540
4.

Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

Brickshawana A, Hinson SR, Romero MF, Lucchinetti CF, Guo Y, Buttmann M, McKeon A, Pittock SJ, Chang MH, Chen AP, Kryzer TJ, Fryer JP, Jenkins SM, Cabre P, Lennon VA.

Lancet Neurol. 2014 Aug;13(8):795-806. doi: 10.1016/S1474-4422(14)70141-3. Epub 2014 Jul 6.

5.

Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.

Kraus V, Srivastava R, Kalluri SR, Seidel U, Schuelke M, Schimmel M, Rostasy K, Leiz S, Hosie S, Grummel V, Hemmer B.

Neurology. 2014 Feb 11;82(6):470-3. doi: 10.1212/WNL.0000000000000097. Epub 2014 Jan 10.

PMID:
24415573
6.

Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?

Brill L, Goldberg L, Karni A, Petrou P, Abramsky O, Ovadia H, Ben-Hur T, Karussis D, Vaknin-Dembinsky A.

Mult Scler. 2015 Apr;21(5):572-9. doi: 10.1177/1352458514551779. Epub 2014 Nov 12.

PMID:
25392324
7.

Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.

Malyavantham K, Weinstock-Guttman B, Suresh L, Zivadinov R, Shanahan T, Badgett D, Ramanathan M.

PLoS One. 2015 Jun 11;10(6):e0129503. doi: 10.1371/journal.pone.0129503. eCollection 2015.

8.
9.

Anti-KIR4.1 Antibodies in Chinese Patients with Central Nervous System Inflammatory Demyelinating Disorders.

Zhong R, Liang J, Tao A, Wu L, Yang X, Xu H, Huang Q, Zhuang S, Long Y, Gao C.

Neuroimmunomodulation. 2016;23(5-6):295-300. doi: 10.1159/000452764. Epub 2017 Apr 8.

PMID:
28391264
10.

Potassium channel KIR4.1 as an immune target in multiple sclerosis.

Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B.

N Engl J Med. 2012 Jul 12;367(2):115-23. doi: 10.1056/NEJMoa1110740.

11.

Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.

Schirmer L, Srivastava R, Kalluri SR, Böttinger S, Herwerth M, Carassiti D, Srivastava B, Gempt J, Schlegel J, Kuhlmann T, Korn T, Reynolds R, Hemmer B.

Ann Neurol. 2014 Jun;75(6):810-28. doi: 10.1002/ana.24168. Epub 2014 May 21.

PMID:
24777949
12.

Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.

Marino M, Frisullo G, Di Sante G, Samengo DM, Provenzano C, Mirabella M, Pani G, Ria F, Bartoccioni E.

Mult Scler. 2018 Jun;24(7):910-918. doi: 10.1177/1352458517711275. Epub 2017 May 26.

PMID:
28548026
13.

Multiple Sclerosis and Antibodies against KIR4.1.

Pröbstel AK, Kuhle J, Lecourt AC, Vock I, Sanderson NS, Kappos L, Derfuss T.

N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131. No abstract available.

14.

Multiple sclerosis: KIR4.1 as an autoantigen in MS--new questions raised.

Killock D.

Nat Rev Neurol. 2014 Aug;10(8):426. doi: 10.1038/nrneurol.2014.128. Epub 2014 Jul 22. No abstract available.

PMID:
25048658
15.

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO.

Higuchi O, Nakane S, Sakai W, Maeda Y, Niino M, Takahashi T, Fukazawa T, Kikuchi S, Fujihara K, Matsuo H.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 22;3(5):e263. doi: 10.1212/NXI.0000000000000263. eCollection 2016 Oct.

16.

Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.

Chastre A, Hafler DA, O'Connor KC.

N Engl J Med. 2016 Apr 14;374(15):1495-6. doi: 10.1056/NEJMc1513302. No abstract available.

17.

Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?

Hemmer B.

Mult Scler. 2015 Apr;21(5):537-9. doi: 10.1177/1352458514564493. Epub 2015 Jan 12. No abstract available.

PMID:
25583849
18.

Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination.

Nakajima M, Kawamura T, Tokui R, Furuta K, Sugino M, Nakanishi M, Okuyama S, Furukawa Y.

Brain Res. 2013 Nov 6;1537:340-9. doi: 10.1016/j.brainres.2013.09.024. Epub 2013 Sep 23.

PMID:
24070676
19.
20.

Inwardly rectifying potassium channel Kir4.1 is responsible for the native inward potassium conductance of satellite glial cells in sensory ganglia.

Tang X, Schmidt TM, Perez-Leighton CE, Kofuji P.

Neuroscience. 2010 Mar 17;166(2):397-407. doi: 10.1016/j.neuroscience.2010.01.005. Epub 2010 Jan 14.

Supplemental Content

Support Center